Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05895006 · ClinicalTrials.gov registry record · NA

A Neurosensory Account of Anxiety and Stress (Study 1)

A NA study of Posttraumatic Stress Disorder (PTSD) and Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT05895006: Recruiting NA study of Posttraumatic Stress Disorder (PTSD) and Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition, sponsored by The University of Texas Health Science Center, Houston.

NCT05895006 is a NA study of Posttraumatic Stress Disorder (PTSD) and Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 160 participants, above the 107-participant average among 31 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (50% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05895006, a NA study of Posttraumatic Stress Disorder (PTSD) and Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

This study will take a basic neuroscience approach to investigate pathological mechanisms underlying PTSD. Additionally, the study aims to identify how Transcranial Alternating Current Stimulation (tACS) brain stimulation can modulate and correct neural networks and related emotions of anxious arousal and hypervigilance, with the goal of assessing tACS brain stimulation technology as a novel intervention for symptoms of anxiety.

Interventions

  • DEVICE Sham for Transcranial Alternating Current Stimulation (tACS)
  • DEVICE Transcranial Random Noise stimulation (tRNS)
  • DEVICE Alternating Current Stimulation (tACS)

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-04-05
Est. Completion 2026-12-31
Phase NA

What NCT05895006 shows while recruiting

NCT05895006 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 31 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (50% higher).

The record links to 2 conditions, with Posttraumatic Stress Disorder (PTSD) appearing as the primary indexed condition, and to 3 interventions - of which Sham for Transcranial Alternating Current Stimulation (tACS) is the first listed.

NCT05895006 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05895006 about?

NCT05895006 is a clinical study titled "A Neurosensory Account of Anxiety and Stress (Study 1)". This study will take a basic neuroscience approach to investigate pathological mechanisms underlying PTSD. Additionally, the study aims to identify how Transcranial Alternating Current Stimulation (tACS) brain stimulation can modulate and correct neural networks and related emotions of anxious arous...

What is the current status of trial NCT05895006?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2022-04-05. Estimated completion is 2026-12-31.

What conditions does trial NCT05895006 study?

This clinical trial studies the following conditions: Posttraumatic Stress Disorder (PTSD), Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition.

What interventions are being tested in trial NCT05895006?

The interventions under investigation include: Sham for Transcranial Alternating Current Stimulation (tACS) (DEVICE), Transcranial Random Noise stimulation (tRNS) (DEVICE), Alternating Current Stimulation (tACS) (DEVICE).

Who is sponsoring clinical trial NCT05895006?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05895006 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Posttraumatic Stress Disorder (PTSD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05895006's enrollment target sits among peer trials

160 8th of 31 higher than 22 of 31 other Posttraumatic Stress Disorder (PTSD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Posttraumatic Stress Disorder (PTSD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05895006, the US trial registry maintained by the National Library of Medicine. NCT05895006 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.